Fenwick Represents Attovia Therapeutics in $105M Oversubscribed Series B Financing

Fenwick represented Attovia Therapeutics, a developer of a pipeline of biotherapeutics with an initial focus on immune-mediated diseases, in its $105 million oversubscribed Series B financing. The round was led by Goldman Sachs Alternatives with participation by new and existing investors.

Attovia will use the funds to advance their lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand their immunology and inflammation pipeline, and to further develop the ATTOBODY™ platform. More information can be obtained from the company’s announcement.

The Fenwick transaction team was led by corporate partner Matt Rossiter and included associates Kristen Nicol and Ryan Kidman.